IMMUNOCORE HLDGS ADS/1(6YG)

Description: Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

---

Keywords: Biotechnology Cancer Diabetes Autoimmune Disease Treatment Of Cancer Immunotherapy Tumor Immunotherapies Melanoma Virotherapy Pd 1 And Pd L1 Inhibitors Solid Tumor Cancers Chronic Hepatitis B Virus Immunocore Immunosuppression Uveal Melanoma Mek Inhibitor Cutaneous Melanoma F106 C M113 V

---

Home Page: www.immunocore.com

92 Park Drive
Abingdon, OX14 4RY
United Kingdom
Phone: 44 12 3543 8600

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)